115 results about "Interstitial lung disease" patented technology

The invention discloses an interstitial lung disease diagnosis method and system based on artificial intelligence, and the method comprises the steps: carrying out the structural processing of clinical data of a patient, constructing a multi-dimensional hypergraph structure, inputting a variational graph auto-encoder model under a constraint condition, carrying out the coding, and introducing a pathological feature constraint to generate a hidden variable; extracting high-order features by using an artificial intelligence multi-dimensional hypergraph neural network, and inputting the high-order features into a diagnosis model based on a deep neural network for optimization training; and finally, processing to-be-detected data according to the same process, calculating a diagnosis probability value, and outputting a result in combination with a threshold value. The system comprises six units including a data structured processing unit, a coding feature extraction unit, a feature aggregation unit, a model training optimization unit, a diagnosis reasoning unit and a result generation unit which are mutually connected and cooperatively work. Through multi-dimensional hypergraph modeling and a pathological constraint mechanism, the problems of poor multi-modal data fusion and lack of pathological feature constraints of a traditional method are effectively solved, and efficient and accurate diagnosis of interstitial lung diseases is realized.

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

To provide compounds as new proline derivatives, and to provide a pharmaceutical composition comprising the compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis, non-alcoholic steatohepatitis, interstitial lung disease and idiopathic pulmonary fibrosis.SOLUTION: There are provided new proline derivatives of formula (I) as cGAS inhibitors, or pharmaceutical compositions comprising a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

A computer implemented method for quantifying and predicting the progression of interstitial lung disease is disclosed herein. The method comprises obtaining at least one image based on a scan of at least a part of a patient's lung, segmenting the image to obtain a lung mask defining the periphery of the lung and to identify structures within the lung mask, and applying a weighting to the identified structures based on the relative position of the structures relative to the lung periphery to obtain a weighted score. The method may then comprise quantifying the extent of interstitial lung disease, and / or predicting the progression of interstitial lung disease, based on the weighted score.

The invention relates to a layered prediction method and system for the risk of malignant tumors related to dermatomyositis. The method comprises the following steps: collecting clinical index data of a patient suffering from dermatomyositis, the clinical index data comprising an anti-TIF1-gamma antibody detection result, an interstitial lung disease existence state, a dermatomyosis existence state, an anemia state and a dermatomyositis type; constructing a comprehensive scoring model to generate a risk stratification prediction result according to the clinical index data; the comprehensive scoring model is used for performing binary assignment on each index to obtain a score of a corresponding item; calculating the sum of scores of all indexes of the patient to obtain a total risk score; and layering the risk of the malignant tumor accompanied by the patient based on the total risk score, and outputting a risk layering result. According to the method, the cancer risk of the patient with dermatomyositis can be effectively predicted, and the reliability, convenience and practicability of layered prediction of the cancer risk are improved.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

The invention includes dry powder nintedanib formulation for dispersion and inhalation administration including salts thereof, indolinone derivative or salts thereof and in fixed dose combinations with carrier agents and other active ingredients. The aerosol delivery combination formulation may be administered as an inhaled aerosol over a few actuations or by two or more actuations. Each dose may be administered one or more times daily on a regular or interval daily dosing regimen. The special formulation parameters of the invention include the selection of the salt for complexation with the form of nintedanib used for an isolated dry powder along with particle size distributions and combination with a force control agent for improved aerosol delivery. Methods of the invention include therapeutically effective doses of the described invention used to treat interstitial lung disease.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject, the medicament comprising, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

The invention relates to the technical field of medical informatics, and provides an interstitial lung disease HRCT image analysis method and system based on artificial intelligence. The method comprises the following steps: performing pulmonary parenchyma segmentation processing on an input HRCT image to obtain a pulmonary parenchyma region; performing multi-category lesion segmentation on the pulmonary parenchyma region to obtain a segmentation mask; performing quantitative calculation on lesion distribution characteristics according to the segmentation mask to obtain lesion distribution parameters; and carrying out image mode classification according to the segmentation mask and the lesion distribution parameters to obtain a classification result. According to the method, the efficiency and precision of HRCT image analysis are improved, and the application range of HRCT image analysis is expanded.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention relates to the field of pharmaceutical compositions, in particular to a nintedanib-containing pharmaceutical composition or pharmaceutical composition for resisting progressive fibrotic interstitial lung disease (PF-ILD), which comprises a therapeutically effective amount of nintedanib or pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs or derivatives of nintedanib, or pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs or derivatives of nintedanib, or pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs or derivatives of nintedanib. Optionally a pharmaceutically acceptable carrier; the composition has a synergistic inhibition effect on lung fibroblast proliferation through combined administration, can be applied to PF-ILD through inhalation combined administration or prepared into a fixed-dose inhalation compound preparation, especially to patients with idiopathic pulmonary fibrosis (IPF), and aims to solve the problems that the treatment effect is insufficient and the treatment effect is poor in the prior art. The safety and the tolerance are poor.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg, anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention discloses an oxygenating nebulizer for treating interstitial lung disease, and relates to an oxygenating nebulizer. The oxygenating nebulizer for treating interstitial lung disease comprises an nebulizer body, wherein a main pipe is fixedly provided at one end of the front bottom of the nebulizer body, a docking joint is fixedly provided at the front side of the main pipe, an arc-shaped pushing plate is slidingly provided on the inner wall of the docking joint near one end, and a rotating frame is fixedly provided in the middle of one side of the arc-shaped pushing plate. By providing the arc-shaped pushing plate and the docking joint, one end of the external pipe is propped up under the action of the docking joint, so that the external pipe and the docking joint can be in close contact. A well-fixed pipe can ensure smooth internal airflow, avoid changes in airflow velocity and pressure distribution due to pipe deformation, and a stable airflow environment prevents droplets from changing particle size due to mutual collision, aggregation or fragmentation when moving in the pipe, thereby slowing down pipe aging. A stable pipe can reduce the impact on components connected thereto.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The invention discloses a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating interstitial lung diseases. The traditional Chinese medicine composition is prepared from, by weight, 5-25 parts of radix asteris, 1-15 parts of ginseng, 1-20 parts of poria cocos, 1-5 parts of pseudo-ginseng, 1-15 parts of angelica sinensis, 1-10 parts of schisandra chinensis, 1-15 parts of rhizoma anemarrhenae, 1-5 parts of cinnamon and 1-15 parts of pericarpium citri reticulatae.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating interstitial lung disease with fibrosis and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 5-15 parts of ginseng, 8-15 parts of radix asparagi, 10-20 parts of radix rehmanniae recen, 15-25 parts of astragalus membranaceus, 5-15 parts of schisandra chinensis, 15-25 parts of honey-fried radix asteris, 15-25 parts of honey-fried flos farfarae, 8-15 parts of curcuma zedoary, 8-15 parts of peach kernels and 8-15 parts of herba epimedii. , 15-30 parts of semen lepidii, 10-20 parts of fructus liquidambaris, and 10-20 parts of semen sinapis. The traditional Chinese medicine composition provided by the invention has the effects of strengthening vitality, reducing phlegm, activating blood, removing blood stasis and dredging collaterals, and can improve clinical symptoms of patients with interstitial lung diseases and fibrosis, improve life quality and delay disease progression.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The present disclosure relates to methods of treating interstitial lung disease by administering (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)-oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid (an LPA1 antagonist).

The disclosure describes methods and compositions for reducing the level or activity of metabotropic glutamate receptor 5 (mGluR5) or / and cannabinoid receptor 1 (CB1R) for the treatment of fibrotic disorders such as pulmonary fibrotic disorders (e.g., fibrosing interstitial lung discases). In some embodiments, a mGluR5 antagonist or / and a CB1R antagonist (c.g., a peripheral CB1R antagonist) is / are used to treat a fibrotic disorder such as a pulmonary fibrotic disorder (e.g., a fibrosing interstitial lung disease).

The application belongs to the technical field of image recognition, and discloses a weakly supervised interstitial lung disease lesion recognition method based on multiple example learning, which comprises the following steps: step 1: acquiring CT image samples; step 2: selecting part of the CT images, and manually labeling the lung parenchyma in the images; step 3: establishing a lung parenchyma segmentation model through a saliency segmentation algorithm, inputting the manually labeled CT image samples to perform training and testing, and obtaining a trained lung parenchyma segmentation model; step 4: training a lesion recognition model using a multiple example learning algorithm; step 5: acquiring a to-be-recognized CT image sample, inputting the lung parenchyma segmentation model to perform segmentation, and then inputting the segmented data sample into the lesion recognition model to obtain a lesion position. The application can realize the visual labeling of interstitial lung disease through a small amount of labeling, and greatly improves the recognition efficiency.

The objective is to provide methods for treating interstitial lung disease, mitigating lung function decline in individuals with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in individuals suffering from ILD. [Solution] A method for treating pulmonary hypertension caused by a condition selected from chronic lung disease, hypoxia, and combinations thereof, comprising administering an effective amount of treprostinil, its prodrug, or a pharmaceutically acceptable salt thereof to a subject with pulmonary hypertension caused by a condition selected from chronic lung disease, hypoxia, and combinations thereof.

The present invention provides pharmaceutical compounds of formula I wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have the meanings given in the specification, which are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases such as idiopathic pulmonary fibrosis and sarcoidosis. # imgabs0 #

The present disclosure relates to oral formulations of n-pyridinylacetamide derivatives and the use of such formulations in the treatment of interstitial lung diseases.

The invention belongs to the technical field of biology, and particularly relates to application of an Mgst2 gene serving as a target to preparation of a product for treating rheumatoid arthritis related interstitial lung diseases. According to the invention, it is found for the first time that Mgst2 can be used as a biomarker for treatment of rheumatoid arthritis related interstitial lung diseases, targeted knock-down is carried out on Mgst2 in neutrophils through an AAV9-shRNA vector (AAV9-shRNA-Mgst2) driven by a Cd11b promoter, and lung lesion progress can be effectively relieved by inhibiting NET formation. The Mgst2 inhibitor provided by the invention can directly intervene in the occurrence and development process of diseases from a molecular level, and has the advantages of accurate effect, remarkable curative effect, low side effect and the like. Compared with a traditional non-specific treatment mode, the product takes effect only aiming at specific molecular targets, damage to normal cells and tissues is remarkably reduced, and therefore the risk of toxic and side effects is reduced.

A traditional Chinese medicine composition and a traditional Chinese medicine decoction are used for preventing and / or treating interstitial lung disease. The traditional Chinese medicine composition includes: 25-35 parts of Astragali Radix, 15-25 parts of Codonopsis Radix, 10-15 parts of Atractylodis Macrocephalae Rhizoma, 10-20 parts of Poria, 10-15 parts of Armeniacae Semen Amarum, 10-15 parts of Platycodonis Radix, 10-20 parts of Salviae Miltiorrhizae Radix et Rhizoma, 10-20 parts of Chuanxiong Rhizoma, 10-15 parts of Angelicae Sinensis Radix, 4-10 parts of Schisandrae Chinensis Fructus, and 5-12 parts of Glycyrrhizae Radix et Rhizoma. These ingredients together have the effects of strengthening and replenishing (the spleen and the lung), activating blood and dissolving stasis, and relieving cough and asthma, thereby preventing and / or treating interstitial lung disease.